NCT07418450

Brief Summary

During EBUS staging in patients with mediastinal lymphadenopathy, it is planned to perform a first round of staging with change of the needle between all lymph nodes and a second round of staging without change of the needle.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
11mo left

Started Nov 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress37%
Nov 2025May 2027

Study Start

First participant enrolled

November 5, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

February 10, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 18, 2026

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2027

Last Updated

February 18, 2026

Status Verified

February 1, 2026

Enrollment Period

1.5 years

First QC Date

February 10, 2026

Last Update Submit

February 10, 2026

Conditions

Lung Cancer (Diagnosis)

Outcome Measures

Primary Outcomes (1)

  • Agreement between the two rounds of EBUS staging

    18 months

Study Arms (1)

STudy group

EXPERIMENTAL
Diagnostic Test: EBUS-TBNA

Interventions

EBUS-TBNADIAGNOSTIC_TEST

During EBUS staging, the needle well be changed between all lymph node stations in a first round. The EBUS staging will be repeated without the change of the needle between the lymph node stations.

STudy group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Pulmonary lesion suspicious for lung cancer or histologically confirmed lung cancer
  • indication for mediastinal staging

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna

Vienna, Austria

RECRUITING

MeSH Terms

Conditions

Lung NeoplasmsDisease

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Daniela Gompelmann

CONTACT

0043 1 40400 47730daniela.gompelmann@meduniwien.ac.at

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr. med.

Study Record Dates

First Submitted

February 10, 2026

First Posted

February 18, 2026

Study Start

November 5, 2025

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 1, 2027

Last Updated

February 18, 2026

Record last verified: 2026-02

Locations

AU(1)